{"transactions":[{"id":4639647,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":183175,"kind":"person","name":"Aguirre Jarrad Mattieu","position":1,"cik":"0002150331","reported_name":"Aguirre Jarrad Mattieu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-10-13T21:17:56.000Z","date":"2026-10-12","kind":"sale","planned":false,"acquired":false,"shares":422,"price":8.63,"value":3641.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $8.54 to $8.63 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information\nregarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":19857,"source":{"system":"sec-edgar","filing":"0002150331-26-000003","document":"form4-10132026_091052.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2150331/000215033126000003/form4-10132026_091052.xml","form_type":"4"}},{"id":4615283,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":39325,"kind":"person","name":"Shook David","position":1,"cik":"0001959742","reported_name":"Shook David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-10T23:37:41.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":500,"price":12.7,"value":6350.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $12.32 to $12.70 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information\nregarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":20423,"source":{"system":"sec-edgar","filing":"0001959742-26-000003","document":"form4-09102026_110937.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1959742/000195974226000003/form4-09102026_110937.xml","form_type":"4"}},{"id":4615275,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":183175,"kind":"person","name":"Aguirre Jarrad Mattieu","position":1,"cik":"0002150331","reported_name":"Aguirre Jarrad Mattieu","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Option (right to buy)","published_at":"2026-09-10T23:31:56.000Z","date":"2026-09-10","kind":"grant","planned":false,"acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"12.5% of the option shares will vest on February 28, 2027, with the remaining option shares to vest in equal monthly installments over the following 42 months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":47500,"derivative":{"exercise_price":12.2,"expiration_date":"2036-09-09","underlying":"Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0002150331-26-000002","document":"form4-09102026_110951.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2150331/000215033126000002/form4-09102026_110951.xml","form_type":"4"}},{"id":676207,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:37.000Z","date":"2026-08-21","kind":"sale","planned":false,"acquired":false,"shares":9589,"price":15.54,"value":149013.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":63899,"source":{"system":"sec-edgar","filing":"0001327111-26-000006","document":"form4-08252026_080833.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711126000006/form4-08252026_080833.xml","form_type":"4"}},{"id":676236,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-08-25T20:05:18.000Z","date":"2026-08-21","kind":"sale","planned":false,"acquired":false,"shares":989,"price":15.54,"value":15369.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":16816,"source":{"system":"sec-edgar","filing":"0001866154-26-000006","document":"form4-08252026_080813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615426000006/form4-08252026_080813.xml","form_type":"4"}},{"id":676204,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19929,"kind":"person","name":"Lee Gary K.","position":1,"cik":"0001907345","reported_name":"Lee Gary K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-25T20:03:19.000Z","date":"2026-08-21","kind":"sale","planned":false,"acquired":false,"shares":1457,"price":15.54,"value":22641.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":16220,"source":{"system":"sec-edgar","filing":"0001907345-26-000006","document":"form4-08252026_080815.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000190734526000006/form4-08252026_080815.xml","form_type":"4"}},{"id":691042,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":24712,"kind":"person","name":"Bulis Veronica Sanchez","position":1,"cik":"0002095702","reported_name":"Bulis Veronica Sanchez","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Corporate Controller"}}],"security":"Common Stock","published_at":"2026-08-11T20:21:52.000Z","date":"2026-08-10","kind":"sale","planned":false,"acquired":false,"shares":621,"price":14.34,"value":8905.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.20 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":14799,"source":{"system":"sec-edgar","filing":"0002095702-26-000005","document":"form4-08112026_080848.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095702/000209570226000005/form4-08112026_080848.xml","form_type":"4"}},{"id":690862,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19929,"kind":"person","name":"Lee Gary K.","position":1,"cik":"0001907345","reported_name":"Lee Gary K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-11T20:20:38.000Z","date":"2026-08-10","kind":"sale","planned":false,"acquired":false,"shares":131,"price":14.34,"value":1878.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.22 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":17677,"source":{"system":"sec-edgar","filing":"0001907345-26-000004","document":"form4-08112026_080834.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000190734526000004/form4-08112026_080834.xml","form_type":"4"}},{"id":690893,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-08-11T20:18:15.000Z","date":"2026-08-10","kind":"sale","planned":false,"acquired":false,"shares":89,"price":14.34,"value":1276.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.27 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":17805,"source":{"system":"sec-edgar","filing":"0001866154-26-000004","document":"form4-08112026_080811.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615426000004/form4-08112026_080811.xml","form_type":"4"}},{"id":690861,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-11T20:07:51.000Z","date":"2026-08-10","kind":"sale","planned":false,"acquired":false,"shares":390,"price":14.34,"value":5592.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.22 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":73488,"source":{"system":"sec-edgar","filing":"0001327111-26-000004","document":"form4-08112026_080842.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711126000004/form4-08112026_080842.xml","form_type":"4"}},{"id":703085,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":28601,"kind":"organization","name":"Innovative Cellular Therapeutics Holdings Ltd","position":1,"cik":"0002095697","reported_name":"Innovative Cellular Therapeutics Holdings Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-07-28T01:14:06.000Z","date":"2026-07-27","kind":"other","planned":false,"acquired":false,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock transferred by the Reporting Person to Wuxiong, Inc. as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 2,818,980 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 44,000 shares transferred."}],"balance_after":2774980,"source":{"system":"sec-edgar","filing":"0001140361-26-029817","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095697/000114036126029817/form4.xml","form_type":"4"}},{"id":703083,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":28601,"kind":"organization","name":"Innovative Cellular Therapeutics Holdings Ltd","position":1,"cik":"0002095697","reported_name":"Innovative Cellular Therapeutics Holdings Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-07-27T23:59:55.000Z","date":"2026-07-27","kind":"other","planned":false,"acquired":false,"shares":38500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock transferred by the Reporting Person to LifeSci Advisors, LLC as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 2,857,480 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 38,500 shares transferred."}],"balance_after":2818980,"source":{"system":"sec-edgar","filing":"0001140361-26-029791","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095697/000114036126029791/form4.xml","form_type":"4"}},{"id":705918,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":28601,"kind":"organization","name":"Innovative Cellular Therapeutics Holdings Ltd","position":1,"cik":"0002095697","reported_name":"Innovative Cellular Therapeutics Holdings Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-07-20T18:55:54.000Z","date":"2026-07-17","kind":"sale","planned":true,"acquired":false,"shares":10,"price":13.7,"value":137.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects 2,857,490 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold."}],"balance_after":2857480,"source":{"system":"sec-edgar","filing":"0001140361-26-028955","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095697/000114036126028955/form4.xml","form_type":"4"}},{"id":707167,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":28601,"kind":"organization","name":"Innovative Cellular Therapeutics Holdings Ltd","position":1,"cik":"0002095697","reported_name":"Innovative Cellular Therapeutics Holdings Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-07-18T01:45:08.000Z","date":"2026-07-16","kind":"sale","planned":true,"acquired":false,"shares":10,"price":13.73,"value":137.3,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects 2,857,500 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold."}],"balance_after":2857490,"source":{"system":"sec-edgar","filing":"0001140361-26-028846","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095697/000114036126028846/form4.xml","form_type":"4"}},{"id":721661,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":28601,"kind":"organization","name":"Innovative Cellular Therapeutics Holdings Ltd","position":1,"cik":"0002095697","reported_name":"Innovative Cellular Therapeutics Holdings Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-07-01T16:37:28.000Z","date":"2026-06-29","kind":"other","planned":false,"acquired":false,"shares":76000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock transferred by the Reporting Person to Wuxiong, Inc. as broker commission in connection with the Upfront Payment (as such term is defined in the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 2,933,500 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 76,000 shares transferred."}],"balance_after":2857500,"source":{"system":"sec-edgar","filing":"0001140361-26-027140","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095697/000114036126027140/form4.xml","form_type":"4"}},{"id":732484,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":28601,"kind":"organization","name":"Innovative Cellular Therapeutics Holdings Ltd","position":1,"cik":"0002095697","reported_name":"Innovative Cellular Therapeutics Holdings Ltd","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-06-19T01:59:08.000Z","date":"2026-06-15","kind":"other","planned":false,"acquired":false,"shares":66500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock transferred by the Reporting Person to LifeSci Advisors, LLC as broker commission in connection with the Upfront Payment (as such term is defined in the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 3,000,000 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 66,500 shares transferred. All shares are held directly and registered in the name of the Reporting Person."}],"balance_after":2933500,"source":{"system":"sec-edgar","filing":"0001140361-26-025796","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095697/000114036126025796/form4.xml","form_type":"4"}},{"id":737865,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-15T22:37:17.000Z","date":"2026-05-11","kind":"sale","planned":false,"acquired":false,"shares":388,"price":18.91,"value":7337.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.15 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":73878,"source":{"system":"sec-edgar","filing":"0001327111-26-000003","document":"form4-06152026_100612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711126000003/form4-06152026_100612.xml","form_type":"4"}},{"id":737864,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19929,"kind":"person","name":"Lee Gary K.","position":1,"cik":"0001907345","reported_name":"Lee Gary K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-15T22:35:24.000Z","date":"2026-05-11","kind":"sale","planned":false,"acquired":false,"shares":130,"price":18.92,"value":2459.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,000 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":17808,"source":{"system":"sec-edgar","filing":"0001907345-26-000003","document":"form4-06152026_100619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000190734526000003/form4-06152026_100619.xml","form_type":"4"}},{"id":737963,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-15T22:34:03.000Z","date":"2026-05-11","kind":"sale","planned":false,"acquired":false,"shares":89,"price":18.92,"value":1683.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 188 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":17894,"source":{"system":"sec-edgar","filing":"0001866154-26-000003","document":"form4-06152026_100659.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615426000003/form4-06152026_100659.xml","form_type":"4"}},{"id":738182,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":24712,"kind":"person","name":"Bulis Veronica Sanchez","position":1,"cik":"0002095702","reported_name":"Bulis Veronica Sanchez","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Corporate Controller"}}],"security":"Common Stock","published_at":"2026-06-15T22:32:20.000Z","date":"2026-05-11","kind":"sale","planned":false,"acquired":false,"shares":217,"price":18.91,"value":4103.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":15420,"source":{"system":"sec-edgar","filing":"0002095702-26-000004","document":"form4-06152026_100616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095702/000209570226000004/form4-06152026_100616.xml","form_type":"4"}},{"id":740044,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-06-12T20:25:08.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":9250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":9250,"derivative":{"exercise_price":13.22,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":9250},"source":{"system":"sec-edgar","filing":"0001182471-26-000002","document":"form4-06122026_080603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000118247126000002/form4-06122026_080603.xml","form_type":"4"}},{"id":740042,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38775,"kind":"person","name":"Ramachandra Sumant","position":1,"cik":"0001439368","reported_name":"Ramachandra Sumant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-06-12T20:23:41.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":9250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":9250,"derivative":{"exercise_price":13.22,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":9250},"source":{"system":"sec-edgar","filing":"0001439368-26-000002","document":"form4-06122026_080637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000143936826000002/form4-06122026_080637.xml","form_type":"4"}},{"id":740043,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38776,"kind":"person","name":"NABEL ELIZABETH G","position":1,"cik":"0001619929","reported_name":"NABEL ELIZABETH G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-06-12T20:22:12.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":9250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":9250,"derivative":{"exercise_price":13.22,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":9250},"source":{"system":"sec-edgar","filing":"0001619929-26-000004","document":"form4-06122026_080608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000161992926000004/form4-06122026_080608.xml","form_type":"4"}},{"id":740041,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-06-12T20:21:00.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":9250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":9250,"derivative":{"exercise_price":13.22,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":9250},"source":{"system":"sec-edgar","filing":"0001591178-26-000002","document":"form4-06122026_080656.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000159117826000002/form4-06122026_080656.xml","form_type":"4"}},{"id":740039,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38772,"kind":"person","name":"FRIEDMAN CATHY","position":1,"cik":"0001411874","reported_name":"FRIEDMAN CATHY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-06-12T20:19:19.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":9250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the\nReporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":9250,"derivative":{"exercise_price":13.22,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":9250},"source":{"system":"sec-edgar","filing":"0001411874-26-000002","document":"form4-06122026_080616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141187426000002/form4-06122026_080616.xml","form_type":"4"}},{"id":740040,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38773,"kind":"person","name":"BRAWLEY OTIS W","position":1,"cik":"0001213029","reported_name":"BRAWLEY OTIS W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-06-12T20:17:30.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":9250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":9250,"derivative":{"exercise_price":13.22,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":9250},"source":{"system":"sec-edgar","filing":"0001213029-26-000007","document":"form4-06122026_080623.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000121302926000007/form4-06122026_080623.xml","form_type":"4"}},{"id":740038,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38771,"kind":"person","name":"Bachleda Mark","position":1,"cik":"0001887762","reported_name":"Bachleda Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-06-12T20:16:06.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":9250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":9250,"derivative":{"exercise_price":13.22,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":9250},"source":{"system":"sec-edgar","filing":"0001887762-26-000002","document":"form4-06122026_080602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000188776226000002/form4-06122026_080602.xml","form_type":"4"}},{"id":741962,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":39325,"kind":"person","name":"Shook David","position":1,"cik":"0001959742","reported_name":"Shook David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-11T20:07:50.000Z","date":"2026-06-10","kind":"sale","planned":false,"acquired":false,"shares":1977,"price":12.64,"value":24989.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,000 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":20923,"source":{"system":"sec-edgar","filing":"0001959742-26-000002","document":"form4-06112026_080646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1959742/000195974226000002/form4-06112026_080646.xml","form_type":"4"}},{"id":841722,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":60665,"kind":"person","name":"Shah Smital","position":1,"cik":"0001808821","reported_name":"Shah Smital","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Fin. and Bus. Officer"}}],"security":"Option (right to buy)","published_at":"2026-03-16T19:26:24.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option shares will vest on March 9, 2027, with the remaining option shares to vest in equal monthly installments over the following 36 months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":140000,"derivative":{"exercise_price":25.5,"expiration_date":"2036-03-08","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001808821-26-000006","document":"form4-03162026_110321.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808821/000180882126000006/form4-03162026_110321.xml","form_type":"4"}},{"id":853633,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":32127,"kind":"organization","name":"ARCH Venture Partners IX, LLC","position":1,"cik":"0001723174","reported_name":"ARCH Venture Partners IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32124,"kind":"organization","name":"ARCH Venture Partners IX, L.P.","position":2,"cik":"0001723173","reported_name":"ARCH Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32125,"kind":"organization","name":"ARCH Venture Partners IX Overage, L.P.","position":3,"cik":"0001723172","reported_name":"ARCH Venture Partners IX Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32121,"kind":"organization","name":"ARCH Venture Fund IX, L.P.","position":4,"cik":"0001666306","reported_name":"ARCH Venture Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32122,"kind":"organization","name":"ARCH Venture Fund IX Overage, L.P.","position":5,"cik":"0001666307","reported_name":"ARCH Venture Fund IX Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-09T20:36:20.000Z","date":"2026-03-06","kind":"purchase","planned":false,"acquired":true,"shares":488090,"price":25.61,"value":12499984.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP.  Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1426528,"source":{"system":"sec-edgar","filing":"0001012975-26-000235","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000101297526000235/form4.xml","form_type":"4"}},{"id":853893,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":1,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":3,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20890,"kind":"person","name":"BERNS PAUL L","position":8,"cik":"0001202769","reported_name":"BERNS PAUL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":9,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-09T20:34:54.000Z","date":"2026-03-06","kind":"purchase","planned":false,"acquired":true,"shares":488090,"price":25.61,"value":12499984.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP.  Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1426528,"source":{"system":"sec-edgar","filing":"0001012975-26-000234","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000101297526000234/form4.xml","form_type":"4"}},{"id":907684,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-13T01:47:49.000Z","date":"2026-02-11","kind":"sale","planned":false,"acquired":false,"shares":7455,"price":23.39,"value":174372.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.7850 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":74266,"source":{"system":"sec-edgar","filing":"0001327111-26-000002","document":"form4-02132026_010246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711126000002/form4-02132026_010246.xml","form_type":"4"}},{"id":907749,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-13T01:46:32.000Z","date":"2026-02-11","kind":"sale","planned":false,"acquired":false,"shares":1236,"price":23.39,"value":28910.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.7850 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":17795,"source":{"system":"sec-edgar","filing":"0001866154-26-000002","document":"form4-02132026_010228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615426000002/form4-02132026_010228.xml","form_type":"4"}},{"id":907685,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19929,"kind":"person","name":"Lee Gary K.","position":1,"cik":"0001907345","reported_name":"Lee Gary K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-13T01:44:57.000Z","date":"2026-02-11","kind":"sale","planned":false,"acquired":false,"shares":1671,"price":23.39,"value":39084.69,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.6305 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":16938,"source":{"system":"sec-edgar","filing":"0001907345-26-000002","document":"form4-02132026_010253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000190734526000002/form4-02132026_010253.xml","form_type":"4"}},{"id":910136,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2026-02-12T02:05:21.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the \"Vesting Commencement Date\") and thereafter, an additional one fortyeighth\n(1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable\nwith respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date."}],"balance_after":65000,"derivative":{"exercise_price":23.71,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001866154-26-000001","document":"form4-02122026_020218.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615426000001/form4-02122026_020218.xml","form_type":"4"}},{"id":910135,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-12T02:05:21.000Z","date":"2026-02-10","kind":"sale","planned":false,"acquired":false,"shares":109,"price":23.12,"value":2520.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":19031,"source":{"system":"sec-edgar","filing":"0001866154-26-000001","document":"form4-02122026_020218.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615426000001/form4-02122026_020218.xml","form_type":"4"}},{"id":910134,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-12T02:05:21.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's\nboard of directors on the Transaction Date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 390 shares acquired on November 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":19140,"source":{"system":"sec-edgar","filing":"0001866154-26-000001","document":"form4-02122026_020218.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615426000001/form4-02122026_020218.xml","form_type":"4"}},{"id":910043,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19929,"kind":"person","name":"Lee Gary K.","position":1,"cik":"0001907345","reported_name":"Lee Gary K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2026-02-12T02:04:20.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the \"Vesting Commencement Date\") and thereafter, an additional one fortyeighth\n(1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable\nwith respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date."}],"balance_after":50000,"derivative":{"exercise_price":23.71,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001907345-26-000001","document":"form4-02122026_020216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000190734526000001/form4-02122026_020216.xml","form_type":"4"}},{"id":910042,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19929,"kind":"person","name":"Lee Gary K.","position":1,"cik":"0001907345","reported_name":"Lee Gary K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-12T02:04:20.000Z","date":"2026-02-10","kind":"sale","planned":false,"acquired":false,"shares":147,"price":23.12,"value":3398.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":18609,"source":{"system":"sec-edgar","filing":"0001907345-26-000001","document":"form4-02122026_020216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000190734526000001/form4-02122026_020216.xml","form_type":"4"}},{"id":910041,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19929,"kind":"person","name":"Lee Gary K.","position":1,"cik":"0001907345","reported_name":"Lee Gary K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-12T02:04:20.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's\nboard of directors on the Transaction Date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 390 shares acquired on November 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":18756,"source":{"system":"sec-edgar","filing":"0001907345-26-000001","document":"form4-02122026_020216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000190734526000001/form4-02122026_020216.xml","form_type":"4"}},{"id":910037,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (right to buy)","published_at":"2026-02-12T02:03:03.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twelve and one-half percent (12.5%) of the total number of shares of Common Stock\nsubject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the \"Vesting Commencement Date\")\nand thereafter, an additional one forty-eighth (1/48th) of the shares will become vested and exercisable\nmonthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month,\non the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of\nthe shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting\ndate."}],"balance_after":155000,"derivative":{"exercise_price":23.71,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001327111-26-000001","document":"form4-02122026_020200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711126000001/form4-02122026_020200.xml","form_type":"4"}},{"id":910036,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-12T02:03:03.000Z","date":"2026-02-10","kind":"sale","planned":false,"acquired":false,"shares":438,"price":23.12,"value":10126.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":81721,"source":{"system":"sec-edgar","filing":"0001327111-26-000001","document":"form4-02122026_020200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711126000001/form4-02122026_020200.xml","form_type":"4"}},{"id":910035,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-12T02:03:03.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 20,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date."}],"balance_after":82159,"source":{"system":"sec-edgar","filing":"0001327111-26-000001","document":"form4-02122026_020200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711126000001/form4-02122026_020200.xml","form_type":"4"}},{"id":910034,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Option (right to buy)","published_at":"2026-02-12T02:01:51.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the \"Vesting Commencement Date\") and thereafter, an additional one fortyeighth\n(1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable\nwith respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date."}],"balance_after":50000,"derivative":{"exercise_price":23.71,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001771329-26-000001","document":"form4-02122026_020247.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000177132926000001/form4-02122026_020247.xml","form_type":"4"}},{"id":910271,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":24712,"kind":"person","name":"Bulis Veronica Sanchez","position":1,"cik":"0002095702","reported_name":"Bulis Veronica Sanchez","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Corporate Controller"}}],"security":"Common Stock","published_at":"2026-02-12T02:00:26.000Z","date":"2026-02-10","kind":"sale","planned":false,"acquired":false,"shares":254,"price":23.12,"value":5872.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":15637,"source":{"system":"sec-edgar","filing":"0002095702-26-000002","document":"form4-02122026_020223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2095702/000209570226000002/form4-02122026_020223.xml","form_type":"4"}},{"id":910270,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":24712,"kind":"person","name":"Bulis Veronica Sanchez","position":1,"cik":"0002095702","reported_name":"Bulis Veronica Sanchez","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Corporate Controller"}}],"security":"Common Stock","published_at":"2026-02-12T02:00:26.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":8750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted under the Issuer's 2021 Equity Incentive Plan.  12.5% of the total number of restricted stock units will vest on August 9, 2026, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":15891,"source":{"system":"sec-edgar","filing":"0002095702-26-000002","document":"form4-02122026_020223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095702/000209570226000002/form4-02122026_020223.xml","form_type":"4"}},{"id":910172,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":39325,"kind":"person","name":"Shook David","position":1,"cik":"0001959742","reported_name":"Shook David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Option (right to buy)","published_at":"2026-02-12T01:58:51.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the \"Vesting Commencement Date\") and thereafter, an additional one fortyeighth\n(1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable\nwith respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date."}],"balance_after":50000,"derivative":{"exercise_price":23.71,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001959742-26-000001","document":"form4-02122026_010247.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1959742/000195974226000001/form4-02122026_010247.xml","form_type":"4"}},{"id":947469,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":24712,"kind":"person","name":"Bulis Veronica Sanchez","position":1,"cik":"0002095702","reported_name":"Bulis Veronica Sanchez","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Corporate Controller"}}],"security":"Common Stock","published_at":"2026-01-06T21:02:57.000Z","date":"2025-12-30","kind":"sale","planned":false,"acquired":false,"shares":936,"price":32.32,"value":30251.52,"ownership":{"direct":true},"balance_after":7141,"source":{"system":"sec-edgar","filing":"0002095702-26-000001","document":"form4-01062026_090153.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2095702/000209570226000001/form4-01062026_090153.xml","form_type":"4"}},{"id":947468,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":24712,"kind":"person","name":"Bulis Veronica Sanchez","position":1,"cik":"0002095702","reported_name":"Bulis Veronica Sanchez","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Corporate Controller"}}],"security":"Common Stock","published_at":"2026-01-06T21:02:57.000Z","date":"2025-12-24","kind":"sale","planned":false,"acquired":false,"shares":1136,"price":38.67,"value":43929.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $38.6643 to $38.6751 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":8077,"source":{"system":"sec-edgar","filing":"0002095702-26-000001","document":"form4-01062026_090153.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095702/000209570226000001/form4-01062026_090153.xml","form_type":"4"}},{"id":1002094,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-13T01:36:42.000Z","date":"2025-11-10","kind":"sale","planned":false,"acquired":false,"shares":412,"price":16.11,"value":6637.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":67159,"source":{"system":"sec-edgar","filing":"0001327111-25-000007","document":"form4-11132025_011139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711125000007/form4-11132025_011139.xml","form_type":"4"}},{"id":1002440,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":24712,"kind":"person","name":"Bulis Veronica Sanchez","position":1,"cik":"0002095702","reported_name":"Bulis Veronica Sanchez","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Corporate Controller"}}],"security":"Common Stock","published_at":"2025-11-13T01:34:59.000Z","date":"2025-11-10","kind":"sale","planned":false,"acquired":false,"shares":239,"price":16.1,"value":3847.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $16.08 to $16.11 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":9213,"source":{"system":"sec-edgar","filing":"0002095702-25-000003","document":"form4-11132025_011155.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2095702/000209570225000003/form4-11132025_011155.xml","form_type":"4"}},{"id":1002093,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19929,"kind":"person","name":"Lee Gary K.","position":1,"cik":"0001907345","reported_name":"Lee Gary K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-11-13T01:33:30.000Z","date":"2025-11-10","kind":"sale","planned":false,"acquired":false,"shares":138,"price":16.16,"value":2230.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":15366,"source":{"system":"sec-edgar","filing":"0001907345-25-000006","document":"form4-11132025_011126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000190734525000006/form4-11132025_011126.xml","form_type":"4"}},{"id":1002144,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-13T01:31:56.000Z","date":"2025-11-10","kind":"sale","planned":false,"acquired":false,"shares":95,"price":16.12,"value":1531.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":15750,"source":{"system":"sec-edgar","filing":"0001866154-25-000006","document":"form4-11132025_011153.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615425000006/form4-11132025_011153.xml","form_type":"4"}},{"id":1012105,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-10-29T21:42:53.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"12.5% of the option shares will vest on April 27, 2026, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":75000,"derivative":{"exercise_price":17.23,"expiration_date":"2035-10-26","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001866154-25-000005","document":"form4-10292025_091048.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000186615425000005/form4-10292025_091048.xml","form_type":"4"}},{"id":1012078,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19929,"kind":"person","name":"Lee Gary K.","position":1,"cik":"0001907345","reported_name":"Lee Gary K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2025-10-29T21:41:36.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":68000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"12.5% of the option shares will vest on April 27, 2026, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":68000,"derivative":{"exercise_price":17.23,"expiration_date":"2035-10-26","underlying":"Common Stock","underlying_shares":68000},"source":{"system":"sec-edgar","filing":"0001907345-25-000005","document":"form4-10292025_091031.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000190734525000005/form4-10292025_091031.xml","form_type":"4"}},{"id":1012076,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (right to buy)","published_at":"2025-10-29T21:40:13.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"12.5% of the option shares will vest on April 27, 2026, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":175000,"derivative":{"exercise_price":17.23,"expiration_date":"2035-10-26","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001327111-25-000006","document":"form4-10292025_091010.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711125000006/form4-10292025_091010.xml","form_type":"4"}},{"id":1058272,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-22T20:07:24.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":7257,"price":10.544,"value":76517.808,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.49 to $10.64 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":67571,"source":{"system":"sec-edgar","filing":"0001415889-25-022747","document":"form4-08222025_080818.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925022747/form4-08222025_080818.xml","form_type":"4"}},{"id":1058271,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-22T20:07:24.000Z","date":"2025-08-20","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 20,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date and 20,000 shares will be issued on August 20, 2026, subject to the reporting person providing service through such date."}],"balance_after":74828,"source":{"system":"sec-edgar","filing":"0001415889-25-022747","document":"form4-08222025_080818.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925022747/form4-08222025_080818.xml","form_type":"4"}},{"id":1058350,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-08-22T20:06:04.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":1004,"price":10.544,"value":10586.176,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.49 to $10.64 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":15845,"source":{"system":"sec-edgar","filing":"0001415889-25-022746","document":"form4-08222025_080857.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000141588925022746/form4-08222025_080857.xml","form_type":"4"}},{"id":1058349,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-08-22T20:06:04.000Z","date":"2025-08-20","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date and 4,000 shares will be issued on August 20, 2026, subject to the reporting person providing service through such date."}],"balance_after":16849,"source":{"system":"sec-edgar","filing":"0001415889-25-022746","document":"form4-08222025_080857.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000141588925022746/form4-08222025_080857.xml","form_type":"4"}},{"id":1058352,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-22T20:03:25.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":1453,"price":10.544,"value":15320.432,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.49 to $10.64 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":15306,"source":{"system":"sec-edgar","filing":"0001415889-25-022741","document":"form4-08222025_080821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925022741/form4-08222025_080821.xml","form_type":"4"}},{"id":1058351,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-22T20:03:25.000Z","date":"2025-08-20","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date and 4,000 shares will be issued on August 20, 2026, subject to the reporting person providing service through such date."}],"balance_after":16759,"source":{"system":"sec-edgar","filing":"0001415889-25-022741","document":"form4-08222025_080821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925022741/form4-08222025_080821.xml","form_type":"4"}},{"id":1058274,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19929,"kind":"person","name":"Lee Gary K.","position":1,"cik":"0001907345","reported_name":"Lee Gary K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-08-22T20:02:06.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":1453,"price":10.544,"value":15320.432,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.49 to $10.64 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":15504,"source":{"system":"sec-edgar","filing":"0001415889-25-022740","document":"form4-08222025_080803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925022740/form4-08222025_080803.xml","form_type":"4"}},{"id":1058273,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19929,"kind":"person","name":"Lee Gary K.","position":1,"cik":"0001907345","reported_name":"Lee Gary K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-08-22T20:02:06.000Z","date":"2025-08-20","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date and 4,000 shares will be issued on August 20, 2026, subject to the reporting person providing service through such date."}],"balance_after":16957,"source":{"system":"sec-edgar","filing":"0001415889-25-022740","document":"form4-08222025_080803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925022740/form4-08222025_080803.xml","form_type":"4"}},{"id":1067863,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-14T01:10:46.000Z","date":"2025-08-12","kind":"sale","planned":false,"acquired":false,"shares":406,"price":10.338,"value":4197.228,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split."}],"balance_after":34828,"source":{"system":"sec-edgar","filing":"0001415889-25-021694","document":"form4-08142025_010843.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925021694/form4-08142025_010843.xml","form_type":"4"}},{"id":1067862,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-14T01:10:46.000Z","date":"2025-08-11","kind":"sale","planned":false,"acquired":false,"shares":391,"price":10.526,"value":4115.666,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split."}],"balance_after":35234,"source":{"system":"sec-edgar","filing":"0001415889-25-021694","document":"form4-08142025_010843.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925021694/form4-08142025_010843.xml","form_type":"4"}},{"id":1067907,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-08-14T01:09:33.000Z","date":"2025-08-12","kind":"sale","planned":false,"acquired":false,"shares":94,"price":10.338,"value":971.772,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split."}],"balance_after":8849,"source":{"system":"sec-edgar","filing":"0001415889-25-021693","document":"form4-08142025_010830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000141588925021693/form4-08142025_010830.xml","form_type":"4"}},{"id":1067906,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-08-14T01:09:33.000Z","date":"2025-08-11","kind":"sale","planned":false,"acquired":false,"shares":91,"price":10.526,"value":957.866,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 390 shares acquired on May 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split."}],"balance_after":8943,"source":{"system":"sec-edgar","filing":"0001415889-25-021693","document":"form4-08142025_010830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000141588925021693/form4-08142025_010830.xml","form_type":"4"}},{"id":1067865,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19929,"kind":"person","name":"Lee Gary K.","position":1,"cik":"0001907345","reported_name":"Lee Gary K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-08-14T01:08:15.000Z","date":"2025-08-12","kind":"sale","planned":false,"acquired":false,"shares":136,"price":10.338,"value":1405.968,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split."}],"balance_after":8957,"source":{"system":"sec-edgar","filing":"0001415889-25-021692","document":"form4-08142025_010810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925021692/form4-08142025_010810.xml","form_type":"4"}},{"id":1067864,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19929,"kind":"person","name":"Lee Gary K.","position":1,"cik":"0001907345","reported_name":"Lee Gary K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-08-14T01:08:15.000Z","date":"2025-08-11","kind":"sale","planned":false,"acquired":false,"shares":131,"price":10.526,"value":1378.906,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 390 shares acquired on May 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split."}],"balance_after":9093,"source":{"system":"sec-edgar","filing":"0001415889-25-021692","document":"form4-08142025_010810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925021692/form4-08142025_010810.xml","form_type":"4"}},{"id":1067911,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-14T01:06:02.000Z","date":"2025-08-12","kind":"sale","planned":false,"acquired":false,"shares":136,"price":10.338,"value":1405.968,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split."}],"balance_after":8759,"source":{"system":"sec-edgar","filing":"0001415889-25-021691","document":"form4-08142025_010858.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925021691/form4-08142025_010858.xml","form_type":"4"}},{"id":1067910,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-14T01:06:02.000Z","date":"2025-08-11","kind":"sale","planned":false,"acquired":false,"shares":131,"price":10.526,"value":1378.906,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Fonn 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 390 shares acquired on May 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split."}],"balance_after":8895,"source":{"system":"sec-edgar","filing":"0001415889-25-021691","document":"form4-08142025_010858.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925021691/form4-08142025_010858.xml","form_type":"4"}},{"id":1115087,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38771,"kind":"person","name":"Bachleda Mark","position":1,"cik":"0001887762","reported_name":"Bachleda Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-06-11T21:48:27.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares of Common Stock subject to the option shall vest on a monthly basis following the grant date on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month), subject to the Reporting Person remaining in service as a director through the applicable vesting date."}],"balance_after":13000,"derivative":{"exercise_price":12.47,"expiration_date":"2035-06-08","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001415889-25-016730","document":"form4-06112025_090624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925016730/form4-06112025_090624.xml","form_type":"4"}},{"id":1115086,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":66896,"kind":"person","name":"Meltz Mark A","position":1,"cik":"0001771329","reported_name":"Meltz Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Option (right to buy)","published_at":"2025-06-11T21:47:11.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option shares will vest on June 9, 2026, with the remaining option shares to vest in equal monthly installments over the following thirty-six months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":12.47,"expiration_date":"2035-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-25-016729","document":"form4-06112025_090608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925016729/form4-06112025_090608.xml","form_type":"4"}},{"id":1115262,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":39325,"kind":"person","name":"Shook David","position":1,"cik":"0001959742","reported_name":"Shook David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Option (right to buy)","published_at":"2025-06-11T21:45:48.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":43750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the option shares will vest on June 9, 2026, with the remaining option shares to vest in equal monthly installments over the following thirty-six months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":43750,"derivative":{"exercise_price":12.47,"expiration_date":"2035-06-08","underlying":"Common Stock","underlying_shares":43750},"source":{"system":"sec-edgar","filing":"0001415889-25-016728","document":"form4-06112025_090645.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1959742/000141588925016728/form4-06112025_090645.xml","form_type":"4"}},{"id":1115261,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":39325,"kind":"person","name":"Shook David","position":1,"cik":"0001959742","reported_name":"Shook David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-06-11T21:45:48.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":21900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted under the Issuer's 2021 Equity Incentive Plan (\"RSUs\").  25% of the total shares subject to the RSUs will vest on June 9, 2026, and an additional 1/16th of the total shares subject to the RSUs per quarter thereafter, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":21900,"source":{"system":"sec-edgar","filing":"0001415889-25-016728","document":"form4-06112025_090645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1959742/000141588925016728/form4-06112025_090645.xml","form_type":"4"}},{"id":1142919,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-05-19T22:50:18.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date."}],"balance_after":130000,"derivative":{"exercise_price":0.4017,"expiration_date":"2035-05-14","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001415889-25-013723","document":"form4-05192025_100514.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925013723/form4-05192025_100514.xml","form_type":"4"}},{"id":1142916,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38777,"kind":"person","name":"RIEFLIN WILLIAM JL","position":1,"cik":"0001182471","reported_name":"RIEFLIN WILLIAM JL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-05-19T22:48:48.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date."}],"balance_after":130000,"derivative":{"exercise_price":0.4017,"expiration_date":"2035-05-14","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001415889-25-013719","document":"form4-05192025_100545.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925013719/form4-05192025_100545.xml","form_type":"4"}},{"id":1142915,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38772,"kind":"person","name":"FRIEDMAN CATHY","position":1,"cik":"0001411874","reported_name":"FRIEDMAN CATHY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-05-19T22:47:00.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date."}],"balance_after":130000,"derivative":{"exercise_price":0.4017,"expiration_date":"2035-05-14","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001415889-25-013712","document":"form4-05192025_100556.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925013712/form4-05192025_100556.xml","form_type":"4"}},{"id":1142914,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38773,"kind":"person","name":"BRAWLEY OTIS W","position":1,"cik":"0001213029","reported_name":"BRAWLEY OTIS W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-05-19T22:45:21.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date."}],"balance_after":130000,"derivative":{"exercise_price":0.4017,"expiration_date":"2035-05-14","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001415889-25-013710","document":"form4-05192025_100517.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925013710/form4-05192025_100517.xml","form_type":"4"}},{"id":1142913,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38776,"kind":"person","name":"NABEL ELIZABETH G","position":1,"cik":"0001619929","reported_name":"NABEL ELIZABETH G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-05-19T22:43:39.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date."}],"balance_after":130000,"derivative":{"exercise_price":0.4017,"expiration_date":"2035-05-14","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001415889-25-013707","document":"form4-05192025_100536.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925013707/form4-05192025_100536.xml","form_type":"4"}},{"id":1142912,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38775,"kind":"person","name":"Ramachandra Sumant","position":1,"cik":"0001439368","reported_name":"Ramachandra Sumant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-05-19T22:41:48.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date."}],"balance_after":130000,"derivative":{"exercise_price":0.4017,"expiration_date":"2035-05-14","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001415889-25-013705","document":"form4-05192025_100544.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925013705/form4-05192025_100544.xml","form_type":"4"}},{"id":1183711,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38773,"kind":"person","name":"BRAWLEY OTIS W","position":1,"cik":"0001213029","reported_name":"BRAWLEY OTIS W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-02T19:46:01.000Z","date":"2025-03-31","kind":"purchase","planned":false,"acquired":true,"shares":35640,"price":0.56,"value":19958.4,"ownership":{"direct":true},"balance_after":35640,"source":{"system":"sec-edgar","filing":"0001415889-25-009604","document":"form4-04022025_070458.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925009604/form4-04022025_070458.xml","form_type":"4"}},{"id":1192308,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38775,"kind":"person","name":"Ramachandra Sumant","position":1,"cik":"0001439368","reported_name":"Ramachandra Sumant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-25T22:46:17.000Z","date":"2025-03-21","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":0.5761,"value":115220.0,"ownership":{"direct":false,"nature":"Grantor and Trustee"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.5487 to $0.5879, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by the Sumant Ramachandra Rev Trust DTD 01/24/12.  The Reporting Person is grantor and trustee of the Sumant Ramachandra Rev Trust DTD 01/24/12."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0001415889-25-008942","document":"form4-03252025_100313.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925008942/form4-03252025_100313.xml","form_type":"4"}},{"id":1200126,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-19T00:07:51.000Z","date":"2025-03-14","kind":"purchase","planned":false,"acquired":true,"shares":158000,"price":0.6009,"value":94942.2,"ownership":{"direct":false,"nature":"Grantor and Trustee"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.59 to $0.62, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 158,000 shares held by The Klausner Family Revocable Trust of May 8, 2014, 245,515 shares held by The Ariella Klausner Delaware Trust, 194,335 shares held by The Eli Klausner Delaware Trust and 245,515 shares held by The Olivia Klausner Delaware Trust (collectively, The Ariella Klausner Delaware Trust, The Eli Klausner Delaware Trust and The Olivia Klausner Delaware Trust, the \"Delaware Trusts\"). The Reporting Person is grantor and trustee of The Klausner Family Revocable Trust of May 8, 2014 and grantor of each of the Delaware Trusts. The JTC Trust Company (Delaware) Limited is the trustee of each of the Delaware Trusts. The Reporting Person disclaims beneficial ownership of all shares held by the Delaware Trusts except to any pecuniary interest therein."}],"balance_after":843365,"source":{"system":"sec-edgar","filing":"0001415889-25-008540","document":"form4-03192025_120347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925008540/form4-03192025_120347.xml","form_type":"4"}},{"id":1200339,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-18T23:01:35.000Z","date":"2025-03-17","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":0.5581,"value":111620.0,"ownership":{"direct":false,"nature":"Co-grantor and Co-trustee"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.54 to $0.56, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by The Charles & Lisa Newton Living Trust.  The Reporting Person is co-trustee and co-grantor of The Charles & Lisa Newton Living Trust."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0001415889-25-008517","document":"form4-03182025_110331.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925008517/form4-03182025_110331.xml","form_type":"4"}},{"id":1200125,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-18T22:59:18.000Z","date":"2025-03-14","kind":"purchase","planned":false,"acquired":true,"shares":175000,"price":0.6068,"value":106190.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.59980 to $0.62020, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range."}],"balance_after":712500,"source":{"system":"sec-edgar","filing":"0001415889-25-008509","document":"form4-03182025_100315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925008509/form4-03182025_100315.xml","form_type":"4"}},{"id":1243447,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":51455,"kind":"person","name":"Lang Matthew","position":1,"cik":"0001712069","reported_name":"Lang Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option (right to buy)","published_at":"2025-02-27T00:36:04.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria."}],"balance_after":56250,"derivative":{"exercise_price":0.5535,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001415889-25-005775","document":"form4-02272025_120200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925005775/form4-02272025_120200.xml","form_type":"4"}},{"id":1243446,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":51455,"kind":"person","name":"Lang Matthew","position":1,"cik":"0001712069","reported_name":"Lang Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Option (right to buy)","published_at":"2025-02-27T00:36:04.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":450000,"derivative":{"exercise_price":0.5535,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001415889-25-005775","document":"form4-02272025_120200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925005775/form4-02272025_120200.xml","form_type":"4"}},{"id":1243445,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":51455,"kind":"person","name":"Lang Matthew","position":1,"cik":"0001712069","reported_name":"Lang Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-27T00:36:04.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting\ndate."}],"balance_after":162500,"source":{"system":"sec-edgar","filing":"0001415889-25-005775","document":"form4-02272025_120200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925005775/form4-02272025_120200.xml","form_type":"4"}},{"id":1243441,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (right to buy)","published_at":"2025-02-27T00:33:46.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":168750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon\nthe achievement of specified performance criteria."}],"balance_after":168750,"derivative":{"exercise_price":0.5535,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":168750},"source":{"system":"sec-edgar","filing":"0001415889-25-005768","document":"form4-02272025_120243.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925005768/form4-02272025_120243.xml","form_type":"4"}},{"id":1243440,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (right to buy)","published_at":"2025-02-27T00:33:46.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":1350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":1350000,"derivative":{"exercise_price":0.5535,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":1350000},"source":{"system":"sec-edgar","filing":"0001415889-25-005768","document":"form4-02272025_120243.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925005768/form4-02272025_120243.xml","form_type":"4"}},{"id":1243439,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-27T00:33:46.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":337500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":537500,"source":{"system":"sec-edgar","filing":"0001415889-25-005768","document":"form4-02272025_120243.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925005768/form4-02272025_120243.xml","form_type":"4"}},{"id":1243488,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-02-27T00:31:23.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria."}],"balance_after":56250,"derivative":{"exercise_price":0.5535,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001415889-25-005760","document":"form4-02272025_120219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000141588925005760/form4-02272025_120219.xml","form_type":"4"}},{"id":1243487,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-02-27T00:31:23.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":450000,"derivative":{"exercise_price":0.5535,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001415889-25-005760","document":"form4-02272025_120219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000141588925005760/form4-02272025_120219.xml","form_type":"4"}},{"id":1243486,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19945,"kind":"person","name":"Hill Stephen J.","position":1,"cik":"0001866154","reported_name":"Hill Stephen J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-02-27T00:31:23.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 7,707 shares acquired on May 17, 2024 and 3,764 shares acquired on  November 18, 2024 under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":172899,"source":{"system":"sec-edgar","filing":"0001415889-25-005760","document":"form4-02272025_120219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866154/000141588925005760/form4-02272025_120219.xml","form_type":"4"}},{"id":1243493,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2025-02-27T00:29:34.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria."}],"balance_after":56250,"derivative":{"exercise_price":0.5535,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001415889-25-005753","document":"form4-02272025_120230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925005753/form4-02272025_120230.xml","form_type":"4"}},{"id":1243492,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2025-02-27T00:29:34.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":450000,"derivative":{"exercise_price":0.5535,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001415889-25-005753","document":"form4-02272025_120230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925005753/form4-02272025_120230.xml","form_type":"4"}},{"id":1243491,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":21269,"kind":"person","name":"Newton Charles W.","position":1,"cik":"0001866219","reported_name":"Newton Charles W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-27T00:29:34.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting\ndate"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 7,800 shares acquired on May 17, 2024 and 3,696 shares acquired on November 18, 2024 under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":172725,"source":{"system":"sec-edgar","filing":"0001415889-25-005753","document":"form4-02272025_120230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1866219/000141588925005753/form4-02272025_120230.xml","form_type":"4"}},{"id":1243444,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19929,"kind":"person","name":"Lee Gary K.","position":1,"cik":"0001907345","reported_name":"Lee Gary K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2025-02-27T00:27:55.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria."}],"balance_after":56250,"derivative":{"exercise_price":0.5535,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001415889-25-005747","document":"form4-02272025_120251.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925005747/form4-02272025_120251.xml","form_type":"4"}}],"next_cursor":"2025-02-27T00:27:55.000000Z,1243444"}